All Research Papers Published In Blood

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.

Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming.

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

CD4+CD25+FOXP3+ Regulatory T Cells to Protect Against Graft Versus Host Disease.

Arterial iron regulates vasodilation during anemia via endothelial holo α-globin.

Menin-MLL inhibitors enhance JUND activity in MLLr leukemic cells contributing to tumorigenesis and therapy resistance.

One-stage Assay Factor VIII Activity Reflects AAV-Derived Factor VIII-Enhanced Thrombin Activation and Predicts Phenotype.

NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma.

IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma.